# Participants of all Risk Tolerances

Our network allows the rich and more risk-tolerant to buy the risk of the poor and more risk-averse. A selling point of our Rejuve Product NFT token is that we enable partners who can't take risks on product completion or wait for returns to get some compensation early and in consistent amounts, through selling Product NFT shards. Individuals may acquire Product NFT shards for the possibility of greater amounts of tokens distributed by pharmaceutical companies upon product sales. When Risky Rick buys NFT shards from Cautious Cassius in an early stage of product development, Rick is hoping for larger amounts of tokens when the product launches. In effect, Rick supports a product’s development with a bet that it will be successful, the bet taking the form of the purchase of Product NFT shards.

Rejuve’s share of NFT sales is used to offer network partners who would not normally return tokens to the network (like wearable and medical equipment companies) a way to join our network through a more traditional business model. The pool of tokens buys the risk of conversions of their tokens to fiat and vice versa, even though the risks are low. Such partners can choose to be paid through what appears to them to be fiat, but underneath are actually tokens that entrepreneurs have put up front in hopes of later reward.

More importantly, buying risk in the form of early-stage Product NFT shards lets product creators and contributors get some money in their pocket without having to wait until the creation is finished, and creates a self-reinforcing system that does not have to be continually fed with subsidies from Rejuve.

To see how this works, say a user fills in a survey. Because there are tokens in the reward pool from NFT shard sales, they can get a reward immediately. The user can use these tokens to buy products and services. The user can utilize these supplements, tests, etc. to create more data, receive tokens from the pool, and then buy more tests and create more data. With enough data in the database, from all these incentives, our crowdsourced AI can use the data to make hypotheses. Then, instead of just Rejuve Tokens, model and data contributors get Product NFT shards for each product that their data contributes to. They can sell up to half (50%) of these shards, so that they still keep half of the proceeds if and when a final pharmaceutical product is sold. Every time someone buys a treatment associated with a product ID associated with the Data NFTs they own, they get more tokens. These long-term rewards are enough to trade in on deep discounts on expensive longevity treatments of all kinds.

The purpose of the entrepreneur is to keep viable products alive by keeping user engagement strong in support of those products. They are effectively crowdfunding products. If someone believes in a particular product, they can buy Product NFT shards from either the individual or the aggregate data owners.
